Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity Study of a 2-dose Immunization Schedule of Recombinant Human Papillomavirus Virus-like Particle Vaccine (Type 16 and 18 L1 Proteins, Yeast) in Adolescent Females Aged 9 to 14 Years

NCT02740777 is registered in ClinicalTrials.gov with Shanghai Zerun Biotechnology Co.,Ltd as lead sponsor.

NCT NCT02740777
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02740777 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity Study of a 2-dose Immunization Schedule of Recombinant Human Papillomavirus Virus-like Particle Vaccine (Type 16 and 18 L1 Proteins, Yeast) in Adolescent Females Aged 9 to 14 Years
Lead sponsor
Shanghai Zerun Biotechnology Co.,Ltd
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2016
Completion date
July 31, 2019
Enrollment
900 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cervical intraepithelial neoplasia, human papillomavirus, persistent infection